Ludvigsson J, Bolli G B
Department of Health and Environment, Linköping University, Sweden.
Diabetes Nutr Metab. 2001 Oct;14(5):292-304.
Intensification of insulin therapy which maintains long-term near-normoglycaemia (HbA1c<7.0%) strongly protects against onset and/or progression of diabetic microangiopathy in Type 1 diabetes mellitus of adults. Similar intensification of insulin therapy is needed in diabetic children as well, in order to prevent complications a few years after diabetes onset, ie very often in young age. Provided adequate psychosocial support and education are available, children should be treated with multiple daily injections of insulin or, when necessary, with continuous subcutaneous insulin infusion, along with blood glucose monitoring. Insulin regimens may differ from child to child and vary from day to day in the same child, depending on lifestyle and considering all the available insulin preparations. These include the short-acting insulin (both human regular and short-acting insulin analogues), the intermediate-acting insulin (NPH and Lente), as well as the new long-acting insulin analogue glargine. The latter seems a promising candidate to substitute of basal insulin. The concern that intensified insulin therapy increases the risk of hypoglycaemia, as indicated by the Diabetes Control and Complications Trial (DCCT), is no longer tenable. On the contrary, a physiological, flexible insulin regimen better than a fixed insulin regimen, usually the twice daily split-mixed regimen, protects against the risk of hypoglycaemia in relation to food ingestion, physical exercise and sleep. Thus, appropriate education should be delivered at diabetes onset to the child and parents in order to start the strategy of intensified insulin therapy as early as possible.
强化胰岛素治疗可维持长期血糖接近正常水平(糖化血红蛋白<7.0%),能有效预防成年1型糖尿病患者糖尿病微血管病变的发生和/或进展。糖尿病儿童也需要类似的强化胰岛素治疗,以预防糖尿病发病几年后的并发症,这种情况在儿童时期很常见。在提供充分的心理社会支持和教育的前提下,应采用胰岛素多次皮下注射治疗儿童糖尿病患者,必要时可采用持续皮下胰岛素输注,并进行血糖监测。胰岛素治疗方案因儿童个体差异而异,即使是同一个儿童,其治疗方案也会因生活方式以及所使用的胰岛素制剂不同而有所变化。这些制剂包括短效胰岛素(人常规胰岛素和短效胰岛素类似物)、中效胰岛素(NPH和Lente)以及新型长效胰岛素类似物甘精胰岛素。后者似乎是替代基础胰岛素的理想选择。糖尿病控制与并发症试验(DCCT)表明强化胰岛素治疗会增加低血糖风险,这种担忧已不再成立。相反,相较于通常为每日两次分剂量混合注射的固定胰岛素治疗方案,灵活的生理性胰岛素治疗方案能更好地预防因饮食摄入、体育锻炼和睡眠导致的低血糖风险。因此,在糖尿病发病初期就应对儿童及其家长进行适当教育,以便尽早开始强化胰岛素治疗策略。